Sequenom (SQNM) Announces Prelim. Q1 Test Volumes, Increases FY Volume Outlook
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Price: $2.39 --0%
Financial Fact:
Cost of diagnostic services: 13.75M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Financial Fact:
Cost of diagnostic services: 13.75M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Sequenom, Inc. (NASDAQ: SQNM) today reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom Center for Molecular Medicine (Sequenom CMM), were accessioned during the first quarter of 2012. This equates to an annualized run rate in excess of 30,000 MaterniT21 PLUS LDTs, based on the volume processed during the last week of the quarter.
Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year.
Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
- Western Digital (WDC) posts FQ3 earnings, revenue beat; shares down
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
Create E-mail Alert Related Categories
Corporate News, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
